USD 156.66
(3.5%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 691.79 Million USD | 0.45% |
2022 | 688.73 Million USD | 18.1% |
2021 | 583.18 Million USD | 30.78% |
2020 | 445.91 Million USD | 46.71% |
2019 | 303.94 Million USD | 28.79% |
2018 | 236 Million USD | 24.78% |
2017 | 189.14 Million USD | 81.52% |
2016 | 104.2 Million USD | 29.49% |
2015 | 80.47 Million USD | -72.72% |
2014 | 294.95 Million USD | 27.56% |
2013 | 231.23 Million USD | 66.47% |
2012 | 138.9 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 680.46 Million USD | 0.95% |
2024 Q1 | 674.09 Million USD | -2.56% |
2023 FY | 691.79 Million USD | 0.45% |
2023 Q2 | 651.74 Million USD | -2.48% |
2023 Q3 | 661.86 Million USD | 1.55% |
2023 Q1 | 668.3 Million USD | -2.97% |
2023 Q4 | 691.79 Million USD | 4.52% |
2022 Q4 | 688.73 Million USD | 6.37% |
2022 Q3 | 647.49 Million USD | 4.03% |
2022 FY | 688.73 Million USD | 18.1% |
2022 Q1 | 602.32 Million USD | 3.28% |
2022 Q2 | 622.39 Million USD | 3.33% |
2021 FY | 583.18 Million USD | 30.78% |
2021 Q1 | 521.06 Million USD | 16.85% |
2021 Q2 | 550.84 Million USD | 5.72% |
2021 Q3 | 552.35 Million USD | 0.27% |
2021 Q4 | 583.18 Million USD | 5.58% |
2020 Q4 | 445.91 Million USD | 1.18% |
2020 Q2 | 418.99 Million USD | 39.8% |
2020 Q1 | 299.71 Million USD | -1.39% |
2020 FY | 445.91 Million USD | 46.71% |
2020 Q3 | 440.71 Million USD | 5.18% |
2019 Q4 | 303.94 Million USD | 2.84% |
2019 FY | 303.94 Million USD | 28.79% |
2019 Q3 | 295.55 Million USD | 1.83% |
2019 Q2 | 290.23 Million USD | 13.17% |
2019 Q1 | 256.45 Million USD | 8.66% |
2018 Q4 | 236 Million USD | 6.92% |
2018 FY | 236 Million USD | 24.78% |
2018 Q1 | 222.53 Million USD | 17.65% |
2018 Q2 | 216.39 Million USD | -2.76% |
2018 Q3 | 220.73 Million USD | 2.01% |
2017 FY | 189.14 Million USD | 81.52% |
2017 Q4 | 189.14 Million USD | 8.78% |
2017 Q3 | 173.87 Million USD | 61.72% |
2017 Q2 | 107.51 Million USD | 5.05% |
2017 Q1 | 102.35 Million USD | -1.78% |
2016 Q3 | 102.07 Million USD | 4.74% |
2016 Q2 | 97.45 Million USD | 15.8% |
2016 Q1 | 84.15 Million USD | 4.57% |
2016 Q4 | 104.2 Million USD | 2.09% |
2016 FY | 104.2 Million USD | 29.49% |
2015 Q4 | 80.47 Million USD | 42.93% |
2015 Q3 | 56.3 Million USD | -81.51% |
2015 Q2 | 304.52 Million USD | 410.91% |
2015 FY | 80.47 Million USD | -72.72% |
2015 Q1 | 59.6 Million USD | -79.79% |
2014 FY | 294.95 Million USD | 27.56% |
2014 Q1 | 51.5 Million USD | 11.89% |
2014 Q3 | 45.14 Million USD | 0.0% |
2014 Q4 | 294.95 Million USD | 553.36% |
2013 FY | 231.23 Million USD | 66.47% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | 46.03 Million USD | 0.0% |
2012 FY | 138.9 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 40.22 Million USD | -1619.778% |
Applied DNA Sciences, Inc. | 8.77 Million USD | -7779.998% |
Aspira Women's Health Inc. | 8.62 Million USD | -7918.987% |
Biodesix, Inc. | 94.51 Million USD | -631.937% |
BioNexus Gene Lab Corp. | 1.74 Million USD | -39614.204% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -20450.712% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -20450.712% |
Bionano Genomics, Inc. | 118.24 Million USD | -485.045% |
CareDx, Inc | 223.28 Million USD | -209.825% |
Check-Cap Ltd. | 1.33 Million USD | -51914.887% |
Castle Biosciences, Inc. | 86.54 Million USD | -699.378% |
DarioHealth Corp. | 38.24 Million USD | -1708.859% |
Exact Sciences Corporation | 3.32 Billion USD | 79.2% |
Fulgent Genetics, Inc. | 139.82 Million USD | -394.767% |
Guardant Health, Inc. | 1.62 Billion USD | 57.499% |
ICON Public Limited Company | 7.74 Billion USD | 91.073% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 61.034% |
Illumina, Inc. | 4.36 Billion USD | 84.155% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | -12263.091% |
iSpecimen Inc. | 6.07 Million USD | -11281.888% |
Standard BioTools Inc. | 159.86 Million USD | -332.739% |
MDxHealth SA | 121.92 Million USD | -467.401% |
23andMe Holding Co. | 206.64 Million USD | -234.773% |
Medpace Holdings, Inc. | 1.09 Billion USD | 36.988% |
Myriad Genetics, Inc. | 312.9 Million USD | -121.092% |
Mainz Biomed B.V. | 12.15 Million USD | -5589.221% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -63068.842% |
NeoGenomics, Inc. | 739.69 Million USD | 6.475% |
Neogen Corporation | 1.44 Billion USD | 51.959% |
Inotiv, Inc. | 588.04 Million USD | -17.645% |
OPKO Health, Inc. | 622.47 Million USD | -11.136% |
Psychemedics Corporation | 6.59 Million USD | -10384.965% |
Prenetics Global Limited | 44.01 Million USD | -1471.795% |
Prenetics Global Limited | 44.01 Million USD | -1471.795% |
Precipio, Inc. | 3.67 Million USD | -18739.815% |
Personalis, Inc. | 95.65 Million USD | -623.199% |
RadNet, Inc. | 2.07 Billion USD | 66.634% |
Sera Prognostics, Inc. | 25.28 Million USD | -2636.218% |
Sotera Health Company | 2.68 Billion USD | 74.251% |
Neuronetics, Inc. | 81.64 Million USD | -747.366% |
Star Equity Holdings, Inc. | 21.67 Million USD | -3091.686% |
Star Equity Holdings, Inc. | 21.67 Million USD | -3091.686% |
Trinity Biotech plc | 83.38 Million USD | -729.653% |
Twist Bioscience Corporation | 152.97 Million USD | -352.241% |
Exagen Inc. | 34.25 Million USD | -1919.848% |